← Browse by Condition
Medical Condition
dll3 expressing tumors
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT07458906
Recruiting
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Enrollment
60 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06788938 Phase 2
Recruiting
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Enrollment
29 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...